A Phase I, Open-label, Randomized, Crossover Study in Healthy Subjects to Evaluate the Bioavailability Of, and the Food Effect On, a Pomalidomide Oral Liquid Suspension

Overview

Journal Clin Pharmacol

Publisher Dove Medical Press

Specialty Pharmacology

Date 2018 Jul 28

PMID 30050331

Citations 1

Authors

Yan Li

Liangang Liu

Lian Huang

Xiaomin Wang

Matthew Hoffmann

Josephine Reyes

Maria Palmisano

Simon Zhou

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study was to evaluate the bioavailability of a pomalidomide oral liquid suspension relative to the commercial capsule formulation and to assess the food effect on the pomalidomide oral liquid suspension when administered as a single 4 mg dose.

Methods: This was an open-label, randomized, three-period, two-sequence crossover study in healthy subjects consisting of a screening phase, a baseline assessment phase, a treatment phase with three periods, and a follow-up phone call phase. Blood samples for pharmacokinetics (PK) assessment were collected up to 48 h postdose during each treatment period. Safety was evaluated throughout the study.

Results: Pomalidomide exposures were comparable in healthy subjects administered with a single oral 4 mg dose as the reference capsule or as the test liquid suspension formulations, demonstrated as the 90% confidence intervals of the geometric mean ratios for area under the plasma concentration-time curve calculated from time 0 to the last measurable concentration at time (AUC), area under the plasma concentration-time curve from time 0 to infinity (AUC), and peak (maximum) plasma drug concentration () were completely contained within the bioequivalence range of 80-125%. Administration of the pomalidomide liquid suspension with a high fat meal resulted in a 3.0 h delay in pomalidomide time to () and an ~ 34.5% reduction in . However, the AUCs were comparable after dose administration with and without food.

Conclusion: A single oral dose of 4 mg of liquid suspension was bioequivalent to a single oral dose of 4 mg of capsule formulation. There was no clinically relevant impact of food on pomalidomide liquid suspension. Single oral doses of 4 mg pomalidomide were safe and well tolerated when administered as a liquid suspension under fed and fasted conditions or as a capsule under fasted conditions.

Citing Articles

Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds.

Radanovic I, Klarenbeek N, Rissmann R, Groeneveld G, van Brummelen E, Moerland M Front Oncol. 2022; 12:954806.

PMID: 36106110 PMC: 9465458. DOI: 10.3389/fonc.2022.954806.

References

Hoffmann M, Kasserra C, Reyes J, Schafer P, Kosek J, Capone L . Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol. 2012; 71(2):489-501. PMC: 3556473. DOI: 10.1007/s00280-012-2040-6. View

Tei K, Maekawa K, Kitada H, Ohiro Y, Yamazaki Y, Totsuka Y . Recovery from postsurgical swallowing dysfunction in patients with oral cancer. J Oral Maxillofac Surg. 2007; 65(6):1077-83. DOI: 10.1016/j.joms.2005.12.082. View

Gay F, Mina R, Troia R, Bringhen S . Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. Expert Opin Drug Metab Toxicol. 2013; 9(11):1517-27. DOI: 10.1517/17425255.2013.827169. View

Richardson P, Siegel D, Vij R, Hofmeister C, Baz R, Jagannath S . Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014; 123(12):1826-32. PMC: 3962162. DOI: 10.1182/blood-2013-11-538835. View

Gupta D, Treon S, Shima Y, Hideshima T, Podar K, Tai Y . Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001; 15(12):1950-61. DOI: 10.1038/sj.leu.2402295. View

Daver N, Shastri A, Kadia T, Newberry K, Pemmaraju N, Jabbour E . Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res. 2014; 38(9):1126-9. PMC: 4157096. DOI: 10.1016/j.leukres.2014.06.015. View

Hideshima T, Chauhan D, Shima Y, Raje N, Davies F, Tai Y . Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000; 96(9):2943-50. View

Lu L, Payvandi F, Wu L, Zhang L, Hariri R, Man H . The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res. 2008; 77(2):78-86. DOI: 10.1016/j.mvr.2008.08.003. View

Lindgren S, Janzon L . Prevalence of swallowing complaints and clinical findings among 50-79-year-old men and women in an urban population. Dysphagia. 1991; 6(4):187-92. DOI: 10.1007/BF02493524. View

10.

Mitsiades N, Mitsiades C, Poulaki V, Chauhan D, Richardson P, Hideshima T . Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002; 99(12):4525-30. DOI: 10.1182/blood.v99.12.4525. View

11.

Li Y, Xu Y, Liu L, Wang X, Palmisano M, Zhou S . Population pharmacokinetics of pomalidomide. J Clin Pharmacol. 2015; 55(5):563-72. PMC: 4418344. DOI: 10.1002/jcph.455. View

12.

Raber-Durlacher J, Brennan M, Verdonck-de Leeuw I, Gibson R, Eilers J, Waltimo T . Swallowing dysfunction in cancer patients. Support Care Cancer. 2011; 20(3):433-43. PMC: 3271214. DOI: 10.1007/s00520-011-1342-2. View

13.

Teo S, Chen Y, Muller G, Chen R, Thomas S, Stirling D . Chiral inversion of the second generation IMiD CC-4047 (ACTIMID ) in human plasma and phosphate-buffered saline. Chirality. 2003; 15(4):348-51. DOI: 10.1002/chir.10221. View

14.

Cleary L . An occupational therapy program for patients with swallowing dysfunction following cancer treatment. Occup Ther Health Care. 2013; 3(2):23-37. DOI: 10.1080/J003v03n02_03. View

15.

Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N . Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005; 128(2):192-203. DOI: 10.1111/j.1365-2141.2004.05286.x. View

16.

Zhu D, Corral L, Fleming Y, Stein B . Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother. 2008; 57(12):1849-59. PMC: 11030653. DOI: 10.1007/s00262-008-0512-7. View

17.

San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M . Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013; 14(11):1055-1066. DOI: 10.1016/S1470-2045(13)70380-2. View

18.

Corral L, Haslett P, Muller G, Chen R, Wong L, Ocampo C . Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999; 163(1):380-6. View

19.

Tjandrawinata R, Setiawati A, Nofiarny D, Susanto L, Setiawati E . Pharmacokinetic equivalence study of nonsteroidal anti-inflammatory drug etoricoxib. Clin Pharmacol. 2018; 10:43-51. PMC: 5896653. DOI: 10.2147/CPAA.S161024. View

20.

Li Y, Zhou S, Hoffmann M, Kumar G, Palmisano M . Modeling and simulation to probe the pharmacokinetic disposition of pomalidomide R- and S-enantiomers. J Pharmacol Exp Ther. 2014; 350(2):265-72. DOI: 10.1124/jpet.114.215251. View